CancerTherapyAdvisor· @CancerTherAdvsr · X·· 1 天前评分70
正文 · 机器翻译
NATALEE：辅助治疗中联合Ribociclib与NSAI改善HR+/HER2-早期乳腺癌的长期生存
Ribociclib联合NSAI治疗与OS的显著改善相关，6年OS率为91.9%，相比NSAI单药的89.7% #ESMO26
🔗 https://bit.ly/4jySLyB
92 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA25按 Proffered paper 1: Breast cancer, early and advanced stage 对上
Adjuvant ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 6-y overall survival (OS) and efficacy outcomes
https://esmocongress.esmo.org来源：CancerTherapyAdvisor · x.com